These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 19193410)
1. DNA Ploidy as surrogate for biopsy gleason score for preoperative organ versus nonorgan-confined prostate cancer prediction. Isharwal S; Miller MC; Epstein JI; Mangold LA; Humphreys E; Partin AW; Veltri RW Urology; 2009 May; 73(5):1092-7. PubMed ID: 19193410 [TBL] [Abstract][Full Text] [Related]
2. Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge. Veltri RW; Miller MC; Mangold LA; O'Dowd GJ; Epstein JI; Partin AW J Urol; 2002 Jul; 168(1):100-4. PubMed ID: 12050500 [TBL] [Abstract][Full Text] [Related]
3. Prediction of pathologic stage and postprostatectomy disease recurrence by DNA ploidy analysis of initial needle biopsy specimens of prostate cancer. Ross JS; Figge H; Bui HX; del Rosario AD; Jennings TA; Rifkin MD; Fisher HA Cancer; 1994 Nov; 74(10):2811-8. PubMed ID: 7954242 [TBL] [Abstract][Full Text] [Related]
4. Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: a report of 454 cases. Sebo TJ; Cheville JC; Riehle DL; Lohse CM; Pankratz VS; Myers RP; Blute ML; Zincke H Cancer; 2001 Jun; 91(11):2196-204. PubMed ID: 11391602 [TBL] [Abstract][Full Text] [Related]
5. DNA image cytometry on biopsies can help the detection of localized Gleason 3+3 prostate cancers. Lorenzato M; Rey D; Durlach A; Bouttens D; Birembaut P; Staerman F J Urol; 2004 Oct; 172(4 Pt 1):1311-3. PubMed ID: 15371830 [TBL] [Abstract][Full Text] [Related]
6. Preoperative neural network using combined magnetic resonance imaging variables, prostate specific antigen and Gleason score to predict prostate cancer stage. Poulakis V; Witzsch U; De Vries R; Emmerlich V; Meves M; Altmannsberger HM; Becht E J Urol; 2004 Oct; 172(4 Pt 1):1306-10. PubMed ID: 15371829 [TBL] [Abstract][Full Text] [Related]
7. Can ploidy of prostate carcinoma diagnosed on needle biopsy predict radical prostatectomy stage and grade? Brinker DA; Ross JS; Tran TA; Jones DM; Epstein JI J Urol; 1999 Dec; 162(6):2036-9. PubMed ID: 10569563 [TBL] [Abstract][Full Text] [Related]
8. An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level. Badalament RA; Miller MC; Peller PA; Young DC; Bahn DK; Kochie P; O'Dowd GJ; Veltri RW J Urol; 1996 Oct; 156(4):1375-80. PubMed ID: 8808875 [TBL] [Abstract][Full Text] [Related]
9. Complexed prostate-specific antigen as a staging tool for prostate cancer: a prospective study in 420 men. Sokoll LJ; Mangold LA; Partin AW; Epstein JI; Bruzek DJ; Dunn W; Mohr P; Wallerson G; Chan DW Urology; 2002 Oct; 60(4 Suppl 1):18-23. PubMed ID: 12384158 [TBL] [Abstract][Full Text] [Related]
10. Prostate volume measured preoperatively predicts for organ-confined disease in men with clinically localized prostate cancer. Bianco FJ; Mallah KN; Korets R; Hricak H; Scardino PT; Kattan MW Urology; 2007 Feb; 69(2):343-6. PubMed ID: 17320675 [TBL] [Abstract][Full Text] [Related]
11. Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance. Perlis N; Sayyid R; Evans A; Van Der Kwast T; Toi A; Finelli A; Kulkarni G; Hamilton R; Zlotta AR; Trachtenberg J; Ghai S; Fleshner NE J Urol; 2017 Jan; 197(1):75-83. PubMed ID: 27457260 [TBL] [Abstract][Full Text] [Related]
12. Prediction of prostate-specific antigen recurrence in men with long-term follow-up postprostatectomy using quantitative nuclear morphometry. Veltri RW; Miller MC; Isharwal S; Marlow C; Makarov DV; Partin AW Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):102-10. PubMed ID: 18199716 [TBL] [Abstract][Full Text] [Related]
13. Preoperative neural network using combined magnetic resonance imaging variables, prostate-specific antigen, and Gleason score to predict positive surgical margins. Poulakis V; Witzsch U; de Vries R; Emmerlich V; Meves M; Altmannsberger HM; Becht E Urology; 2004 Sep; 64(3):516-21. PubMed ID: 15351582 [TBL] [Abstract][Full Text] [Related]
16. PTEN Loss in Gleason Score 3 + 4 = 7 Prostate Biopsies is Associated with Nonorgan Confined Disease at Radical Prostatectomy. Guedes LB; Tosoian JJ; Hicks J; Ross AE; Lotan TL J Urol; 2017 Apr; 197(4):1054-1059. PubMed ID: 27693448 [TBL] [Abstract][Full Text] [Related]
17. Indications for preoperative prostate biopsy in patients undergoing radical cystoprostatectomy for bladder cancer. Thomas C; Wiesner C; Melchior S; Gillitzer R; Schmidt F; Thüroff JW J Urol; 2008 Nov; 180(5):1938-41; discussion 1941. PubMed ID: 18801501 [TBL] [Abstract][Full Text] [Related]
18. Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3). Aus G; Becker C; Lilja H; Khatami A; Pihl CG; Hugosson J Scand J Urol Nephrol; 2003; 37(6):466-70. PubMed ID: 14675918 [TBL] [Abstract][Full Text] [Related]
19. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy. Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340 [TBL] [Abstract][Full Text] [Related]
20. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score. Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]